| 4.1 Antipsychotics |
6 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1.1 Nausea |
4 |
754 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.49, 1.29] |
| 4.1.2 Uneasy feeling |
1 |
60 |
Risk Ratio (M‐H, Random, 95% CI) |
7.00 [0.38, 129.93] |
| 4.1.3 Constipation |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
6.50 [0.41, 104.20] |
| 4.1.4 Dry mouth |
4 |
754 |
Risk Ratio (M‐H, Random, 95% CI) |
2.60 [1.46, 4.64] |
| 4.2 Antipsychotics |
3 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.2.1 liver function: ALT/SGPT baseline to endpoint mean change (U/L) |
2 |
530 |
Std. Mean Difference (IV, Random, 95% CI) |
0.46 [0.29, 0.63] |
| 4.2.2 liver function: AST/SGOT baseline to endpoint mean change (U/L) |
2 |
526 |
Std. Mean Difference (IV, Random, 95% CI) |
0.35 [0.18, 0.52] |
| 4.2.3 liver function: total bilirubin baseline to endpoint mean change (μmol/L) |
1 |
264 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.29 [‐0.53, ‐0.05] |
| 4.2.4 liver function: direct bilirubin baseline to endpoint mean change (μmol/L) |
1 |
258 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.35 [‐0.60, ‐0.11] |
| 4.2.5 liver function: GGT (GGPT/SGGT/YGGT) baseline to endpoint mean change |
1 |
268 |
Std. Mean Difference (IV, Random, 95% CI) |
0.26 [0.02, 0.50] |
| 4.2.6 lipids: total cholesterol baseline to endpoint change (mmol/L) |
2 |
327 |
Std. Mean Difference (IV, Random, 95% CI) |
0.42 [0.20, 0.64] |
| 4.2.7 lipids: LDL cholesterol baseline to endpoint mean change (mmol/L) |
1 |
259 |
Std. Mean Difference (IV, Random, 95% CI) |
0.35 [0.10, 0.59] |
| 4.2.8 lipids: HDL cholesterol (dextran precip.) baseline to endpoint mean change (mmol/L) |
1 |
269 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.28 [‐0.52, ‐0.04] |
| 4.2.9 lipids: triglycerides, fasting, baseline to endpoint mean change (mmol/L) |
1 |
203 |
Std. Mean Difference (IV, Random, 95% CI) |
0.37 [0.09, 0.64] |
| 4.2.10 prolactin: baseline to endpoint mean change (μg/L) |
1 |
259 |
Std. Mean Difference (IV, Random, 95% CI) |
0.32 [0.07, 0.56] |
| 4.2.11 platelet count baseline to endpoint mean change (GI/L) |
2 |
517 |
Std. Mean Difference (IV, Random, 95% CI) |
0.03 [‐0.53, 0.59] |
| 4.2.12 erythrocyte count baseline to endpoint mean change (TI/L) |
1 |
262 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.18 [‐0.42, 0.06] |
| 4.2.13 leukocyte count baseline to endpoint mean change (GI/L) |
1 |
262 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.40 [‐0.65, ‐0.16] |
| 4.2.14 neutrophils, segmented, baseline to endpoint mean change (GI/L) |
1 |
262 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.39 [‐0.63, ‐0.14] |
| 4.2.15 basophils baseline to endpoint mean change (GI/L) |
1 |
262 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.28 [‐0.53, ‐0.04] |
| 4.2.16 monocytes baseline to endpoint mean change (GI/L) |
1 |
262 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.28 [‐0.53, ‐0.04] |
| 4.2.17 haemoglobin baseline to endpoint mean change (mml/L‐F) |
1 |
262 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.21 [‐0.45, 0.03] |
| 4.2.18 mean cell haemoglobin concentration (MCHC) baseline to endpoint mean change (mml/L‐F) |
1 |
260 |
Std. Mean Difference (IV, Random, 95% CI) |
0.03 [‐0.22, 0.27] |
| 4.2.19 calcium baseline to endpoint mean change (mmol/L) |
1 |
268 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.33 [‐0.57, ‐0.09] |
| 4.2.20 albumin baseline to endpoint mean change (g/L) |
1 |
269 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.21 [‐0.45, 0.03] |
| 4.2.21 creatine phosphokinase baseline to endpoint mean change (U/L) |
1 |
268 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.21 [‐0.45, 0.03] |
| 4.2.22 urea nitrogen baseline to endpoint mean change (mmol/L) |
1 |
269 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.14 [‐0.38, 0.10] |
| 4.3 Mood stabilisers |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 4.3.1 gastrointestinal disorders |
1 |
276 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.70 [0.50, 0.98] |
| 4.3.2 general disorders and administration site conditions |
1 |
276 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.50, 2.05] |
| 4.3.3 hepatobiliary disorders |
1 |
276 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.04 [0.13, 74.07] |
| 4.3.4 metabolism and nutrition disorders |
1 |
276 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.03 [0.19, 22.12] |
| 4.4 Memantine hydrochloride |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 4.4.1 constipation |
1 |
33 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [0.59, 4.57] |
| 4.4.2 nausea/vomiting |
1 |
34 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.45, 2.23] |
